Class summary at a glance.

Every drug in the Sulfone class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $11.5Mcombined across class
Total Rx claims: 144K46K unique beneficiaries
Generic mfrs (active): 16across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Dapsone

Brand: ACZONE · 144K Part D claims (CY24) · 46K beneficiaries · First FDA approval: 2009-06-24

16 generic mfrs 0 plans require PA

Low NADAC$0.512

→

Avg plan cost$0.809

Part D spend $11.5M 2× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Dapsone Gel,

Brand: Dapsone · — Part D claims (CY24) · First FDA approval: 2023-10-16

Brand-only (no generics)

Low NADAC$0.767

→

Avg plan cost$0.822

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dapsone Tablets

— Part D claims (CY24) · First FDA approval: 2024-09-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Daspone

Brand: Dapsone · — Part D claims (CY24) · First FDA approval: 2023-06-02

Brand-only (no generics) 0 plans require PA

Low NADAC$0.790

→

Avg plan cost$0.819

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.